Literature DB >> 20023546

Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone.

Mitsuhisa Nishiguchi1, Shigeki Ono, Keiichi Iseda, Hiroaki Manabe, Tomohito Hishikawa, Isao Date.   

Abstract

OBJECTIVE: Cerebral vasospasm remains a major cause of morbidity and mortality. Milrinone, a bipyridine phosphodiesterase III inhibitor, is a potent member of the inodilator class of cardiac agents for vasospasm and is injected intra-arterially or intracisternally. There have been no studies investigating the duration of action (context-sensitive half-life) of milrinone for vasospasm or the most effective route of administration (intra-arterial versus intracisternal). We examined the effects of intracisternal and intra-arterial injection of milrinone on chronic cerebral vasospasm in dogs.
METHODS: A double-hemorrhage canine model was used. In a preliminary isometric tension study of canine vasospastic basilar arteries, the vasodilatory effects of milrinone were examined 7 days after an initial injection of blood. Milrinone was injected intracisternally (0.1 mg, 0.47 mmol/L) or intra-arterially (0.3 mg/kg, 1.2 mmol/L), and angiograms were performed 30, 60, 120, 180, 240, 300, and 360 minutes later on day 7.
RESULTS: Milrinone produced concentration-dependent vasodilation and was effective intracisternally, resulting in significant dilation until 180 minutes after injection and a tendency for dilation until 240 minutes. The effect of intra-arterial injection was not as significant compared with an intracisternal injection, resulting in significant dilation only at 180 minutes after intra-arterial injection.
CONCLUSION: Intracisternal injection of milrinone was more effective than intra-arterial injection for chronic cerebral vasospasm in dogs because intracisternal injection produced a higher concentration in vasospastic arteries (0.034-0.068 mmol/L intracisternally versus 0.016 mmol/L intra-arterially).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20023546     DOI: 10.1227/01.NEU.0000363153.62579.FF

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  11 in total

1.  Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol.

Authors:  Marcelo Lannes; Jeanne Teitelbaum; Maria del Pilar Cortés; Mauro Cardoso; Mark Angle
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

2.  Protective effect of unilateral vasospasm in the setting of HHH-associated posterior reversible encephalopathy syndrome: case report, review of the literature, and treatment considerations.

Authors:  Alankrita Raghavan; Jordan Xu; James M Wright; Christina Huang Wright; Benjamin Miller; Yin Hu
Journal:  Chin Neurosurg J       Date:  2018-12-03

3.  Milrinone via lumbar subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Nobutake Sadamasa; Kazumichi Yoshida; Osamu Narumi; Masaki Chin; Sen Yamagata
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

4.  Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review.

Authors:  Mendel Castle-Kirszbaum; Leon Lai; Julian Maingard; Hamed Asadi; R Andrew Danks; Tony Goldschlager; Ronil V Chandra
Journal:  Neurosurg Rev       Date:  2021-03-08       Impact factor: 3.042

5.  A novel intravital method to evaluate cerebral vasospasm in rat models of subarachnoid hemorrhage: a study with synchrotron radiation angiography.

Authors:  Jun Cai; Yuhao Sun; Falei Yuan; Lujia Chen; Chuan He; Yuhai Bao; Zuoquan Chen; Meiqing Lou; Weiliang Xia; Guo-Yuan Yang; Feng Ling
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 6.  Treatment of Subarachnoid Hemorrhage-associated Delayed Cerebral Ischemia With Milrinone: A Review and Proposal.

Authors:  Thomas D Bernier; Michael J Schontz; Saef Izzy; David Y Chung; Sarah E Nelson; Thabele M Leslie-Mazwi; Galen V Henderson; Hormuzdiyar Dasenbrock; Nirav Patel; Mohammad A Aziz-Sultan; Steven Feske; Rose Du; Yasser B Abulhasan; Mark R Angle
Journal:  J Neurosurg Anesthesiol       Date:  2021-07-01       Impact factor: 3.969

7.  The use of intravenous Milrinone to treat cerebral vasospasm following traumatic subarachnoid hemorrhage.

Authors:  Oliver Lasry; Judith Marcoux
Journal:  Springerplus       Date:  2014-10-27

8.  Anti-high mobility group box-1 (HMGB1) antibody attenuates delayed cerebral vasospasm and brain injury after subarachnoid hemorrhage in rats.

Authors:  Jun Haruma; Kiyoshi Teshigawara; Tomohito Hishikawa; Dengli Wang; Keyue Liu; Hidenori Wake; Shuji Mori; Hideo Kohka Takahashi; Kenji Sugiu; Isao Date; Masahiro Nishibori
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

9.  Basilar artery vasospasm after pretuncal non-aneurysmal subarachnoid hemorrhage responding to milrinone.

Authors:  Abdulrahman Y Alturki; Abdullah S Alamri; Mohamed M Badawy; Benjamin W Lo
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

10.  Sex-specific associations between cerebrovascular blood pressure autoregulation and cardiopulmonary injury in neonatal encephalopathy and therapeutic hypothermia.

Authors:  Raul Chavez-Valdez; Matthew O'Connor; Jamie Perin; Michael Reyes; Jillian Armstrong; Charlamaine Parkinson; Maureen Gilmore; Jacky Jennings; Frances J Northington; Jennifer K Lee
Journal:  Pediatr Res       Date:  2017-01-31       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.